Videos

A urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.

Dr. John J. Kowalczyk identifies the features of integrated, urology-specific software systems that have the largest impact on the management of his practice.

Practice management concerns and considerations for clinicians intending to incorporate software tools into their practice workflows.

An experienced urologist provides an overview of useful niches clinical software tools can fill and how they can serve to boost efficiency in the practice.

John J. Kowalczyk, DO, FACOS describes his own urology practice, touching on patient demographics, staffing, and management strategies.

“These are men who are suffering in silence. Many of them are too embarrassed to ever discuss their sexual health problems,” says Mohit Khera, MD, MBA, MPH.

“We were surprised that only 43% of individuals believed fertility preservation to be important, but this could be due to the relatively low age of our respondents, with the majority being between 18 and 39 years old,” says Niki Parikh, MD, MBA, MSBA.

“It's really the overall excellence of a multidisciplinary program focused on improving patient outcomes,” says Daniel E. Spratt, MD.

“Survival differences can be due in part to genetic differences, but also a lot of socioeconomic issues as well,” says Ridwan Alam, MD.

“Histologic variants do express Nectin-4 and Trop-2, the targets of antibody-drug conjugates that are FDA-approved in bladder cancer,” says Fed Ghali, MD.

Ridwan Alam, MD, discusses research exploring nonclinical factors affecting overall survival in patients with renal cell carcinoma.

Fed Ghali, MD, discusses the outlook for patients with variant histology bladder cancer and how antibody-drug conjugates may provide a new treatment option in this setting.

The researchers stress the need for improved patient education prior to surgery.

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

Dr Stephen Freedland outlines the currently available, NCCN-recommended treatment options for patients with high-risk, clinically localized prostate cancer, and the clinical challenges he faces during the treatment decision-making process.

Stephen J. Freedland, MD, describes the process of diagnosing, grading, staging, and stratifying risk for patients with prostate cancer and the typical tests he uses in his clinical practice.

Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.

A comparison of the safety and efficacy of available AR inhibitors and a discussion of factors that impact treatment selection in mCSPC.

Gordon A. Brown, DO, comments on adverse events observed after combination ADT/apalutamide treatment and how they might be managed.

A comprehensive review of efficacy data on combination therapy with ADT and the AR inhibitor apalutamide in patients with mCSPC.

Dr Gordon Brown provides an overview of single-agent androgen deprivation therapy (ADT) and other regimens that may be used in combination with ADT, including androgen receptor (AR) inhibitors, for treatment of mCSPC.

An expert comments on the patient profile and offers insights into how he approaches treatment and management of prostate cancer.

Gordon A. Brown, DO, presents the profile of a 60-year-old man with prostate cancer.

“There will always be changes. I'm entering my fourth cycle of recertification, and I can tell you that none of the 3 prior cycles were similar,” says David Joseph, MD.

“We are seeing responses,” says Tanya Dorff, MD.

“Guidelines are not a rulebook; they're a framework for how to think about a particular disease,” says Edward M. Schaeffer, MD, PhD.

"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.

The analysis showed promising signs of clinical activity with cabazitaxel/gemcitabine plus pembrolizumab in patients with docetaxel-unresponsive non-muscle invasive urothelial carcinoma of the upper and lower urinary tracts.

Amy N. Luckenbaugh, MD, recaps 5 presentations from the 2022 American Society of Clinical Oncology Annual Meeting.

“The real-world data suggest that the use of tumor sequencing is definitely suboptimal,” says Pedro C. Barata, MD, MSc.